Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
- Andrew StemerAffiliated withUniversity of California Email author
- , Patrick LydenAffiliated withUniversity of California
Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in the acute setting is intravenous thrombolysis. The efficacy and safety of recombinant tissue plasminogen activator (rt-PA) have been firmly established within 3 h of symptom onset; however, few patients are eligible for treatment in this time window. Expanding the time for treatment has been challenging, but new evidence has demonstrated a modest statistical improvement in selected patients when rt-PA is administered within 4.5 h. This important finding hopefully will enable more patients to receive treatment and simultaneously provides an opportunity to reaffirm that the benefits of rt-PA diminish with time.
KeywordsIschemic stroke Intravenous rt-PA ECASS III Time window
- Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Neurology and Neuroscience Reports
Volume 10, Issue 1 , pp 29-33
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Ischemic stroke
- Intravenous rt-PA
- ECASS III
- Time window
- Industry Sectors